RP-593

N/A

Report date: 2023/02/18 16:53:00
NME

Base Information

Drug NameRP-593
Drug Alias Name99mTc-c(RGDfK)2HYNIC(Tc(99))RP593
ClassificationRadiation-emitting productsSmall molecules > Synthetic peptide
Mechanisms of ActionRadionuclide imaging enhancersIntegrin alpha-V/beta-3 antagonists
TargetsIntegrin alpha-V/beta-3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company Bristol-Myers Squibb Holdings Pharma Ltd Liability Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol-Myers Squibb Company Bristol-Myers Squibb Holdings Pharma Ltd Liability Company
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A